Abbott To FDA: Resolve 505(b)(2) Issues Before Approving Depakote Competitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Andrx’ NDA for delayed-release valproate sodium differs from Depakote only in active ingredient and raises the same type of public policy concerns FDA identified in its October 2003 analysis of the approval pathway, an Abbott citizen petition states.